GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Bionano Genomics Inc.
Bionano Genomics produces an optical genome mapping system that complements traditional sequencing. Its stock price is a bet that its technology will become the standard in genetic research. The chart reflects the slow but steady adoption of the technology in scientific laboratories.
Share prices of companies in the market segment - Dna
Bionano Genomics provides the Saphyr platform for optical genome mapping, which enables the analysis of DNA structural variations invisible to other technologies. We've classified it as "DNA." The chart below shows how the market values companies with unique genomics technologies.
Broad Market Index - GURU.Markets
Bionano Genomics is the company that developed the Saphyr platform for analyzing structural genome variations, which aids in genetic research. Its breakthrough technology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Bionano compares to it.
Change in the price of a company, segment, and market as a whole per day
BNGO - Daily change in the company's share price Bionano Genomics Inc.
Bionano Genomics, Inc.'s daily share price fluctuations reflect the extreme volatility of the genomics analysis sector. This metric is a measure of the company's sensitivity to scientific publications and the adoption of its platform by research centers.
Daily change in the price of a set of shares in a market segment - Dna
Bionano Genomics offers genome analysis platforms that help identify structural DNA variations. The genetic research sector is one of the most advanced and volatile in biotech. The chart below shows average fluctuations in this industry, allowing one to assess BNGO's dynamics against the backdrop of general trends.
Daily change in the price of a broad market stock, index - GURU.Markets
Bionano Genomics has developed a platform for analyzing genomes at a structural level, a feat unavailable with traditional methods. The company's shares are a bet on a revolution in genetics. Their high volatility is part of the dynamic nature of the innovative sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Bionano Genomics Inc.
Bionano Genomics' year-over-year performance is a story of the adoption of its optical genome mapping (OGM) platform. Its market capitalization growth over the past 12 months reflects the growing number of laboratories using its Saphyr system for cytogenetic testing. Its valuation is a bet on OGM becoming the new standard in diagnostics.
Annual dynamics of market capitalization of the market segment - Dna
Bionano Genomics, Inc. is a company that has developed a unique platform for optical genome mapping. Its technology helps detect large structural variations missed by other methods. The graph shows how its breakthrough technology and its path to widespread clinical application are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bionano Genomics offers a genomic analysis platform that could revolutionize diagnostics. Its year-over-year market capitalization reflects investor confidence that its technology will become the new standard in genetic research. The company's shares move in sync with scientific publications and the adoption of the technology by the scientific community.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Bionano Genomics Inc.
Bionano Genomics is a genomics company producing a system for optical genome mapping. Its monthly growth reflects the pace of adoption of its Saphyr platform in research labs and growing sales of consumables, which are key to its business model.
Monthly dynamics of market capitalization of the market segment - Dna
Bionano Genomics, Inc. is a genomics company that developed the Saphyr platform for analyzing structural genome variations that are invisible to traditional sequencing methods. The dynamics of its sector, shown in the graph, reflect scientific progress. Against this backdrop, one can appreciate how its unique technology is changing approaches to genetic diagnostics and research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bionano Genomics offers a genomic analysis platform. Its shares are moving on news of its technology being adopted by research centers and sales growth. The chart shows high volatility, typical of companies striving to set a new standard in their industry, ignoring broader market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Bionano Genomics Inc.
Shares of Bionano Genomics, a developer of a genomic analysis system, react sharply to scientific news. Their weekly price movements reflect the progress of the scientific community's acceptance of their technology. The publication of a new study or a conference presentation triggers an immediate reaction from investors.
Weekly dynamics of market capitalization of the market segment - Dna
Bionano Genomics offers a genomic analysis platform that could revolutionize diagnostics. Its shares are highly sensitive to news about technology implementation and scientific publications. A comparison with the sector will reveal whether the company follows its own news cycle or general trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bionano Genomics offers a platform for genomic analysis. Its shares are a bet on a scientific revolution. The chart clearly shows how its performance is detached from the broader market and driven by news about the implementation of its technology and scientific publications.
Market capitalization of the company, segment and market as a whole
BNGO - Market capitalization of the company Bionano Genomics Inc.
Bionano Genomics' market capitalization chart tells the story of investors' faith in the technological revolution in genomics. Its sharp rises reflect hopes that its optical genome mapping system will become a new standard, while its protracted declines reflect the difficult path to commercialization. The scale of this metric, even after correction, speaks to the enormous potential of the cytogenetics market.
BNGO - Share of the company's market capitalization Bionano Genomics Inc. within the market segment - Dna
Bionano Genomics offers an optical genome mapping platform that complements traditional sequencing. Its market share in the life sciences sector reflects its unique technology. Its market capitalization reflects the potential of its Saphyr system for detecting large structural variations in DNA.
Market capitalization of the market segment - Dna
This chart shows the total value of the entire biotech sector focused on genetic analysis. For Bionano Genomics, with its unique genome mapping platform, this line represents the future of medicine. The chart's growth reflects the belief that in-depth analysis of DNA structure will be key to diagnosing and treating complex genetic diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Bionano Genomics has developed a platform for analyzing structural genome variations that other tests miss. Its market capitalization is the value of this "new perspective" on DNA. This represents the market share of this technology, which can uncover new causes of disease.
Book value capitalization of the company, segment and market as a whole
BNGO - Book value capitalization of the company Bionano Genomics Inc.
Bionano Genomics developed the Saphyr optical genome mapping system. Its book value is its technological and production base: R&D centers, patents, and production lines for devices and chips. This is the material foundation for genomic research. How has it grown? The chart below shows.
BNGO - Share of the company's book capitalization Bionano Genomics Inc. within the market segment - Dna
Bionano Genomics, Inc. has created a platform for optical genome mapping. Its innovations require a substantial infrastructure: manufacturing facilities for Saphyr devices and chips, as well as R&D laboratories. The chart shows its share of the physical infrastructure for manufacturing genomic analysis equipment.
Market segment balance sheet capitalization - Dna
Life sciences, as the graph shows, require enormous capital investment. Bionano Genomics is a manufacturer of 'tools' for this capital-intensive industry. Its business consists of R&D and factories that create complex systems for genome analysis. This is a bet on owning a tangible technological platform.
Book value of all companies included in the broad market index - GURU.Markets
Bionano Genomics' book value is not derived from its drugs, but from its factories producing the Saphyr optical genome mapping systems, which allow scientists to detect structural variations in DNA inaccessible to other methods. Its assets reflect its technological leadership in this field of genetic research. The chart shows its weight.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Bionano Genomics Inc.
Bionano Genomics is a game-changer in genomic analysis. Its market value is based on its unique Saphyr platform, which enables the detection of structural variations in the genome. Investors aren't buying hardware, but rather technology that can accelerate medical discoveries.
Market to book capitalization ratio in a market segment - Dna
Bionano Genomics offers a platform for optical genome mapping, a breakthrough technology in genetics. The chart shows a colossal premium to its tangible assets. Investors are betting that its technology will become a new standard in research and diagnostics, transforming the entire industry.
Market to book capitalization ratio for the market as a whole
Bionano Genomics offers a genomic analysis platform that could revolutionize medicine. The company's main asset is its unique technology, not its equipment. This chart shows the enormous premium investors are willing to pay for breakthrough scientific developments capable of transforming entire industries, compared to the average business.
Debts of the company, segment and market as a whole
BNGO - Company debts Bionano Genomics Inc.
Bionano Genomics, a developer of a genomic analysis platform, is using capital to accelerate the commercialization of its technology. Debt funds the deployment of equipment in labs around the world and invests in marketing. This chart shows how the company is using its balance sheet to create a new standard in genomic research.
Market segment debts - Dna
Bionano Genomics has developed the Saphyr system for optical genome mapping, which enables the analysis of DNA structural variations invisible to traditional sequencing methods. This graph illustrates how the company behind this new technology platform is funding its commercialization, aiming to make its method the standard in genetic research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Bionano Genomics Inc.
Bionano Genomics offers an optical genome mapping platform that reveals structural variations inaccessible to other methods. The development and commercialization of such complex systems requires significant investments in R&D and marketing. This chart shows how the company uses debt to finance its innovations in the cutting-edge field of genomics.
Market segment debt to market segment book capitalization - Dna
Bionano Genomics has developed a platform for optical genome mapping that complements traditional sequencing. Implementing this new technology requires significant marketing expenditures. This chart shows how the company is funding this commercialization, comparing its debt to the market capitalization of the entire biotech tools sector.
Debt to book value of all companies in the market
Bionano Genomics offers a genome analysis platform that reveals structural variations inaccessible to other technologies. This is a groundbreaking, but capital-intensive, field. How heavily does the company rely on debt to fund its R&D and commercialization? This chart of total market debt helps assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - Bionano Genomics Inc.
Bionano Genomics has developed the Saphyr system for optical genome mapping, which enables the analysis of large-scale structural variations in DNA. This chart shows how investors value its technology as a complement to traditional sequencing. This valuation depends on the system's adoption in research labs.
P/E of the market segment - Dna
Bionano Genomics provides an optical genome mapping platform that enables the analysis of DNA structural variations inaccessible to traditional sequencing methods. This chart illustrates the average valuation in the genetic research sector, where investors are betting on technologies that can accelerate scientific discovery and improve diagnostics.
P/E of the market as a whole
Bionano Genomics, Inc. provides an optical genome mapping platform that enables the analysis of large-scale structural DNA variations with unprecedented accuracy. This chart reflects overall investor interest in the genomics sector. It helps us understand whether BNGO's high valuation reflects faith in the revolutionary potential of its technology or general market trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Bionano Genomics Inc.
Bionano Genomics has developed an optical genome mapping system that enables the analysis of DNA structural variations inaccessible to traditional sequencing methods. This chart demonstrates the investors' belief that Bionano's technology will become a new standard in genetic research and clinical diagnostics, opening up a huge market.
%20P%2FE%20Bionano%20Genomics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Bionano-Genomics-Inc.&v=1772653777388 "Chart of the company's future (projected) P/E Bionano Genomics Inc.")
Future (projected) P/E of the market segment - Dna
Bionano Genomics offers an optical genome mapping platform that reveals structural variations inaccessible to other technologies. The graph shows the sector's expected future profits, helping to understand the extent to which investors believe Bionano's technology will become the new standard in genetic research.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772653777390 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Bionano Genomics offers an optical genome mapping platform that identifies structural variations invisible to other technologies. It's a revolutionary tool for genetic research. This risk appetite chart shows how willing investors are to invest in breakthrough technologies that could change the future of medicine.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772653777398 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Bionano Genomics Inc.
Bionano Genomics, Inc. developed the Saphyr system for optical genome mapping, which allows researchers to see structural DNA variations inaccessible to other technologies. Revenue comes from sales of systems and consumables. This chart shows how the company monetizes its unique tool, which advances genetic research.
Profit of companies in the market segment - Dna
Bionano Genomics, Inc. has developed a system for optical genome mapping that can detect large structural variations invisible to traditional sequencing methods. This graph illustrates the overall profitability of the life sciences sector, where breakthrough genetic analysis technologies have the potential to revolutionize diagnostics and research.
Overall market profit
Bionano Genomics, Inc. provides a genome analysis platform that helps researchers identify structural variations. The company's growth depends on research budgets and the adoption of its technology in clinical practice. This process is loosely linked to the short-term economic cycles visible in the graph and is determined by the speed of scientific discoveries.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Bionano Genomics Inc.
Bionano Genomics offers an optical genome mapping platform that enables the detection of large structural variations invisible to traditional sequencing methods. Future revenue depends on the adoption of its technology in research and clinical laboratories. This chart shows analysts' expectations for the revolutionary potential of Bionano's technology.
%20profit%20of%20the%20company%20Bionano%20Genomics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Bionano-Genomics-Inc.&v=1772653777427 "Graph of future (projected) profit of the company Bionano Genomics Inc.")
Future (predicted) profit of companies in the market segment - Dna
Bionano Genomics has developed the Saphyr platform for optical genome mapping, which identifies structural variations in DNA missed by other methods. This technology has great potential in genetic diagnostics and research. This graph shows revenue projections for the biotech sector, reflecting how Bionano's innovations are changing genomics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772653777464 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Bionano Genomics, Inc. offers a genome analysis platform that helps identify structural variations. Demand for its products depends on research budgets. This economic outlook influences public and private funding for genetic research, which is essential for Bionano's business.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772653777475 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Bionano Genomics Inc.
Bionano Genomics offers an optical genome mapping platform that reveals structural variations invisible to other technologies. Revenue growth reflects the adoption of this revolutionary technology by research centers. This chart illustrates the significant premium investors are paying for the potential of its platform in the future of genomic medicine.
P/S market segment - Dna
Bionano Genomics has revolutionized genetic analysis with its Saphyr optical genome mapping platform. It allows researchers to see large-scale structural DNA variations inaccessible to other technologies. This graph shows the average revenue estimate for the sector, helping to understand the premium the market is willing to pay for breakthrough genomics technologies.
P/S of the market as a whole
Bionano Genomics provides a platform for optical genome mapping that allows researchers to see structural variations in DNA inaccessible to other technologies. This is a revolutionary tool for genetics. This chart shows how highly the market values companies whose technologies are transforming scientific approaches, compared to average market revenue estimates.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Bionano Genomics Inc.
Bionano Genomics provides an optical genome mapping platform that reveals structural DNA variations inaccessible to other technologies. The company's future revenue estimates are critical for such an innovative company. They reflect investors' belief that its technology will become the standard in genetic research and diagnostics, leading to increased sales of systems and consumables.
%20P%2FS%20Bionano%20Genomics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Bionano-Genomics-Inc.&v=1772653777521 "The graph of the company's future (projected) P/S Bionano Genomics Inc.")
Future (projected) P/S of the market segment - Dna
Bionano Genomics offers an optical genome mapping platform that identifies large structural variations invisible to other technologies. This chart compares the company's estimated future sales with expectations for the life sciences sector. It shows whether investors believe its technology will become a key tool in genetic research and diagnostics.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772653777522 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Bionano Genomics offers an optical genome mapping platform that enables the detection of structural variations invisible to traditional sequencing methods. The company's growth depends on the adoption of its technology in genetic research and diagnostics. This chart of overall market expectations reflects investor confidence in breakthroughs in genomics.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772653777531 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Bionano Genomics Inc.
This chart illustrates Bionano Genomics' revenue from sales of its Saphyr optical genome mapping system. This technology enables the detection of large structural variations in DNA that other methods miss. Revenue growth reflects the adoption of this cutting-edge platform in research and diagnostic labs worldwide for the study of genetic diseases.
Sales of companies in the market segment - Dna
Bionano Genomics offers the Saphyr platform for optical genome mapping, which reveals structural variations invisible to other technologies. Its revenue structure clearly demonstrates a "razor and blades" model: revenue from instrument sales and, more importantly, from consumables, which provide a stable revenue stream.
Overall market sales
Bionano Genomics, Inc. offers a genome analysis platform that reveals structural variations inaccessible to other technologies. The company is revolutionizing genetics, with growth driven by scientific research and clinical translation. This general economics chart doesn't capture the dynamics of this disruptive sector, where value is created through unique data.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Bionano Genomics Inc.
Bionano Genomics provides an optical genome mapping (OGM) platform that detects large structural variations in DNA missed by other technologies. The company's growth depends on the adoption of its system in research and diagnostic laboratories. This chart shows analyst sales forecasts, reflecting their confidence in the future of genomic analysis.
%20sales%20of%20the%20company%20Bionano%20Genomics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Bionano-Genomics-Inc.&v=1772653777645 "Schedule of future (projected) sales of the company Bionano Genomics Inc.")
Future (projected) sales of companies in the market segment - Dna
Bionano Genomics offers an optical genome mapping platform that helps identify structural DNA variations. This graph shows the outlook for the life sciences sector. Is increased investment in genomic research expected, spurring demand for advanced analytical tools? This reflects a general scientific trend.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772653777661 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Bionano Genomics provides a genome analysis platform that helps researchers identify structural variations. Demand for its products comes from academic and research institutions and is driven by their budgets. This graph has an indirect impact: overall economic growth drives increased research funding, which ultimately supports Bionano's business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772653777683 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Bionano Genomics Inc.
Bionano Genomics offers an optical genome mapping platform that identifies structural variations invisible to other technologies. This graph shows the company's progress as it transforms approaches to genetic analysis. Profitability depends on sales of its Saphyr systems and consumables, as well as the expansion of its technology into diagnostics and research.
Market segment marginality - Dna
Bionano Genomics, Inc. provides a platform for optical genome mapping that allows scientists to detect structural DNA variations inaccessible to other methods. This metric reflects the company's financial health, whose profitability depends on the pace of implementation of its unique technology in research labs and clinics worldwide.
Market marginality as a whole
Bionano Genomics provides genomic analysis platforms that help researchers identify structural variations in DNA. Demand for its expensive equipment depends on the budgets of research institutes and biotech companies. This overall profitability chart reflects the economic climate, which influences funding for cutting-edge scientific research.
Employees in the company, segment and market as a whole
Number of employees in the company Bionano Genomics Inc.
Bionano Genomics produces an optical genome mapping system that reveals structural variations invisible to other methods. Its team of scientists and engineers is key to its success. This chart shows how the company is expanding its commercial and scientific staff to bring its Saphyr platform to research labs worldwide.
Share of the company's employees Bionano Genomics Inc. within the market segment - Dna
Bionano Genomics has developed a platform for optical genome mapping that enables the detection of structural variations inaccessible to other technologies. This requires a team of scientists, bioinformaticians, and engineers. This graph shows the company's market share, reflecting its leadership in the unique niche of genomic analysis and its ability to attract scientific talent.
Number of employees in the market segment - Dna
Bionano Genomics offers the Saphyr platform for optical genome mapping, which enables the detection of large structural variations invisible to other technologies. The chart shows employment in the genetic engineering sector. Bionano's technology complements traditional sequencing, and the growing number of geneticists worldwide expands the company's potential client base.
Number of employees in the market as a whole
Bionano Genomics offers a genome analysis platform that helps researchers identify structural variations in DNA. The company's growth is driven by advances in genetics and its applications in medicine. This chart illustrates the big picture, and Bionano is an example of a knowledge-intensive business that creates jobs for highly qualified scientists advancing life sciences.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Bionano Genomics Inc. (BNGO)
Bionano Genomics is changing the game in genetic analysis with its Saphyr platform. It's a business built on breakthrough technology. This chart clearly demonstrates the enormous value the market places on their intellectual property. It shows the market capitalization per employee, reflecting the high valuation of their unique R&D platform.
%20of%20the%20company%20Bionano%20Genomics%20Inc.%20(BNGO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Bionano-Genomics-Inc.-BNGO&v=1772653777785 "Chart of market capitalization per employee (in thousands of dollars) of the company Bionano Genomics Inc. (BNGO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Bionano Genomics (BNGO) offers a platform for optical genome mapping that helps researchers identify structural variations. In the genomics field, market capitalization per employee reflects the value of the technology. A high market capitalization may indicate that the Saphyr platform is unique and indispensable for genetic analysis, generating enormous scientific and commercial value.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772653777814 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Bionano Genomics offers an optical genome mapping platform that reveals structural variations invisible to other methods. The company's value lies in its unique technology. The chart shows a high cost per employee, as its platform is a crucial tool for genetic research and diagnostics.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772653777838 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Bionano Genomics Inc. (BNGO)
Bionano Genomics (BNGO) produces the Saphyr system for optical genome mapping. It's a "razor and blades" model. This chart shows how close the company is to profitability. It reflects how much profit (or loss) the engineering and R&D team generates from selling expensive systems and high-margin consumables.
%20Chart%20Bionano%20Genomics%20Inc.%20(BNGO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Bionano-Genomics-Inc.-BNGO&v=1772653777883 "Company Profit Per Employee (in thousands of dollars) Chart Bionano Genomics Inc. (BNGO)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Bionano Genomics, Inc. offers genomic analysis platforms. In high-tech biotechnology, value is created through intellectual property and breakthrough technologies, not through large staffs. This chart shows the financial return generated by each scientist and engineer, a key indicator of R&D and commercialization effectiveness relative to competitors.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772653777891 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Bionano Genomics provides a platform (Saphyr) for optical genome mapping, revealing structural variations missed by sequencing. It's a "razor and blades" model: they sell equipment and consumables. This graph helps us understand how profitable the "science tools" business, which requires R&D and scientific support, is per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772653777926 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Bionano Genomics Inc. (BNGO)
Bionano Genomics offers an optical genome mapping platform that is transforming genetic research. This chart demonstrates the commercial success of their unique technology. Growing revenue per employee reflects the widespread adoption of their systems in labs worldwide and growing sales of consumables.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Bionano-Genomics-Inc.-BNGO&v=1772653777944 "Sales chart per company employee Bionano Genomics Inc. (BNGO)")
Sales per employee in the market segment - Dna
Bionano Genomics (BNGO) is a "shovel seller" for geneticists. They produce the Saphyr system for optical genome mapping (analysis of large DNA structures). Their business is selling hardware (devices) and consumables. This graph shows the average output in the sector. For BNGO, this is an indicator of how productive their sales and R&D teams are in promoting this complex platform.
Sales per employee for the market as a whole
Bionano Genomics is a game-changer in genetics. Their Saphyr system allows them to "see" major structural changes in DNA that others miss. It's a "razor and blades" model: they sell expensive equipment and the consumables that are constantly needed for it. This graph demonstrates how scalable this science-intensive model is.
Short shares by company, segment and market as a whole
Shares shorted by company Bionano Genomics Inc. (BNGO)
Bionano Genomics (BNGO) is promoting its Saphyr platform for optical genome mapping, aiming to revolutionize genetic analysis. It's a capital-intensive R&D company. This chart shows the number of shares borrowed by speculators. Bears may doubt that BNGO's technology will outperform competitors (like Illumina) or that the company will achieve profitability before it needs further dilutive financing.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Bionano-Genomics-Inc.-BNGO&v=1772653777972 "Short Shares Chart for the Company Bionano Genomics Inc. (BNGO)")
Shares shorted by market segment - Dna
Bionano Genomics (BNGO) offers the Saphyr system for optical genome mapping, which reveals large structural DNA changes inaccessible to other methods. This chart shows the total short position in the "life science tools" sector. It reflects investor concerns about slowing biotech funding, which is reducing laboratory budgets.
Shares shorted by the overall market
Bionano (BNGO) is an R&D project in the field of genomics. It's a "shovel" for biotech. When this chart shows rising fear, it signals a "venture winter." This means BNGO's clients (small biotechs) are freezing R&D and stopping buying its expensive, unproven equipment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Bionano Genomics Inc. (BNGO)
Bionano Genomics (BNGO) provides the Saphyr platform for optical genome mapping, which helps identify large structural variations, which is important for genetic research and diagnostics. This oscillator measures momentum. It shows when stocks are "overheated" (above 70) on breakout news or "oversold" (below 30) due to slow technology adoption.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Bionano-Genomics-Inc.-BNGO&v=1772653778081 "RSI 14 indicator chart for the company's stock Bionano Genomics Inc. (BNGO)")
RSI 14 Market Segment - Dna
Bionano Genomics (BNGO) is a company that has revolutionized genomics. Its Saphyr system analyzes "optical genome maps" (OGMs)—super-long DNA molecules—inaccessible to sequencers. This graph measures the collective momentum of the gene and DNA technology (or "life science tools") sector. It helps distinguish the reaction to BNGO's technology from the general "emotional" wave affecting the entire industry.
RSI 14 for the overall market
For Bionano Genomics (BNGO), a developer of genomic platforms, this chart is an indicator of R&D budgets. In times of euphoria, biotech companies and labs (its clients) are generously funded and buying new equipment. In times of panic and recession, R&D budgets are cut, and the purchase of expensive "innovative" platforms is postponed.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BNGO (Bionano Genomics Inc.)
Bionano Genomics (BNGO) is the manufacturer of the Saphyr system, which performs optical genome mapping (OGM). This unique method analyzes large structural variations in DNA. This chart shows the average analyst forecast. Their targets are based on the growth of the Saphyr installed base and, more importantly, sales of consumables (chips).
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BNGO-Bionano-Genomics-Inc.&v=1772653778112 "A chart showing analyst consensus forecasts for the expected stock price. BNGO (Bionano Genomics Inc.)")
The difference between the consensus estimate and the actual stock price BNGO (Bionano Genomics Inc.)
Bionano Genomics (BNGO) is a company changing the "map" of the genome. Their Saphyr platform allows for the "optical map"—the major structural changes in DNA that sequencers miss. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the implementation of this technology in R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BNGO-Bionano-Genomics-Inc.&v=1772653778124 "A chart showing the difference between the consensus forecast and the actual stock price. BNGO (Bionano Genomics Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Bionano Genomics (BNGO) is a company changing the "map" of the genome. Its Saphyr system allows it to "see" major structural changes in DNA that other tests miss. This chart shows general expectations for the DNA technology sector, reflecting whether experts believe in the revolution of "optical" genome mapping.
Analysts' consensus forecast for the overall market share price
Bionano Genomics (BNGO) is a "mapper" of the genome. Their device (Saphyr) isn't sequencing, but rather "optical mapping," which detects large structural changes in DNA that are invisible to others. This graph shows the overall risk appetite. It reflects the level of confidence analysts place in the R&D budgets of Big Pharma, BNGO's clients.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Bionano Genomics Inc.
Bionano Genomics (BNGO) is a genome mapper. They don't just read (like Illumina), but see the big picture: their platform (Saphyr) visualizes structural changes in DNA that (they claim) older sequencing misses. This graph is a summary indicator of their adoption history. It reflects their (slow) ability to sell razors (machines) and blades (consumables).
AKIMA Market Segment Index - Dna
Bionano Genomics (BNGO) doesn't read DNA, it maps it. Their Saphyr (OGM) system allows scientists to identify major structural changes in the genome that traditional sequencers miss. This chart shows the average index for the segment, helping investors assess the relevance of this mapping technology in the genetic engineering sector.
The AKIM Index for the overall market
Bionano Genomics is a company that provides optical genome mapping solutions (Saphyr) for identifying structural DNA variations. This chart, which reflects the market average, is a backdrop. It helps assess how BNGO, a cytogenetics tool, compares to general macroeconomic trends in science.
